Evonile Pharma Limited
NSE: EVONILE · Pharmaceuticals
Share price ₹1,367.60
down 1.82% · close of 20 Nov 2026
Your ratios
Market cap
₹4,784 Cr
P/E ratio
74.4
EPS TTM to Sep 2026
P/B ratio
6.2
ROCE
16.3%
ROE
11.6%
Dividend yield
0.0%
as of 19 Nov 2026
1 · Overview
Overview
Price, valuation, sales and profit over the range you pick. Prices as of the last close; results as filed.
One candle a week · body: open to close, green when it closed higher · line: high to low
At a glance · 1Yr
Every small chart follows the range above. Point at it to read a value; click it to open it.2 · Results
Latest result · Q2 FY27
What the last results showed. Whether management kept its word is in Pro.
Net profit -₹78.0 Cr, down 425.0% on Sep 2025
Earnings call transcript · 4 Nov 2026
12 years, Mar 2015 to Mar 2026, and the last 12 months · key lines
| Line | Mar 2015FY15 | Mar 2016FY16 | Mar 2017FY17 | Mar 2018FY18 | Mar 2019FY19 | Mar 2020FY20 | Mar 2021FY21 | Mar 2022FY22 | Mar 2023FY23 | Mar 2024FY24 | Mar 2025FY25 | Mar 2026FY26 | TTMto Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales₹ crore | 870.00 | 690.00change on a year before -21% | 656.00change on a year before -5% | 564.00change on a year before -14% | 491.00change on a year before -13% | 438.00change on a year before -11% | 381.00change on a year before -13% | 400.00change on a year before +5% | 379.00change on a year before -5% | 335.07change on a year before -12% | 356.27change on a year before +6% | 354.33 | 337.00change on a year before -5% |
| Expenses₹ crore | 874 | 656 | 631 | 570 | 478 | 426 | 355 | 373 | 314 | 270 | 265 | 260 | 291 |
| Change in inventories₹ crore | -12.21 | ||||||||||||
| Goods bought for resale₹ crore | 210.58 | ||||||||||||
| Employee cost₹ crore | 21.08 | ||||||||||||
| Other expenses₹ crore | 40.78 | ||||||||||||
| Operating profit₹ crore | -4 | 34 | 25change on a year before -26% | -6change on a year before -124% | 12 | 12change on a year before 0% | 27change on a year before +125% | 27change on a year before 0% | 65change on a year before +141% | 65change on a year before 0% | 91change on a year before +40% | 94 | 46change on a year before -54% |
| Operating margin% of sales | -0.40% | 5.00% | 3.80% | -1.10% | 2.50% | 2.80% | 7.00% | 7.00% | 17.00% | 19.00% | 26.00% | 27.00% | 13.65% |
| Gross margin% of sales | 44.02% | ||||||||||||
| Other income₹ crore | 101 | 207 | 71 | 172 | 78 | 36 | 33 | -17 | 58 | 62 | 42 | 39 | -33 |
| Interest₹ crore | 0.00 | 0.00 | 1.00 | 6.00 | 2.00 | 6.00 | 8.00 | 5.00 | 2.00 | 1.00 | 0.77 | 1.26 | 6.00 |
| Depreciation₹ crore | 4.00 | 3.00 | 4.00 | 3.00 | 3.00 | 13.00 | 12.00 | 10.00 | 6.00 | 2.61 | 2.19 | 1.95 | 4.00 |
| Profit before tax₹ crore | 93.00 | 237.00 | 92.00 | 158.00 | 86.00 | 29.00 | 40.00 | -4.00 | 115.00 | 122.84 | 130.42 | 129.66 | 2.00 |
| Tax rate% of profit before tax | 15.00% | 16.00% | 38.00% | 50.00% | 40.00% | 65.00% | 48.00% | -3.00% | 10.00% | 31.00% | 23.00% | 28.00% | |
| Net profit₹ crore | 79.00 | 198.00change on a year before +151% | 57.00change on a year before -71% | 78.00change on a year before +37% | 52.00change on a year before -33% | 10.00change on a year before -81% | 21.00change on a year before +110% | -4.00change on a year before -119% | 103.00 | 85.19change on a year before -17% | 100.90change on a year before +18% | 93.18 | -5.00change on a year before -105% |
| EPS₹ per share | 20.82 | 52.18change on a year before +151% | 17.13change on a year before -67% | 26.74change on a year before +56% | 17.67change on a year before -34% | 3.44change on a year before -81% | 7.13change on a year before +107% | -1.27change on a year before -118% | 35.28 | 29.08change on a year before -18% | 34.44change on a year before +18% | 31.80 | -1.36change on a year before -104% |
| Dividend paid out% of net profit | 40.00% | 16.00% | 49.00% | 32.00% | 48.00% | 245.00% | 118.00% | -663.00% | 113.00% | 72.00% | 61.00% | 66.00% |
Small figure: change on the year before (TTM: on the 12 months to Sep 2025). TTM = the four quarters to Sep 2026. Lines that are 0 or blank in every column are not shown.
The last 13 quarters, Sep 2023 to Sep 2026 · key lines
| Line | Sep 2023Q2 FY24 | Dec 2023Q3 FY24 | Mar 2024Q4 FY24 | Jun 2024Q1 FY25 | Sep 2024Q2 FY25 | Dec 2024Q3 FY25 | Mar 2025Q4 FY25 | Jun 2025Q1 FY26 | Sep 2025Q2 FY26 | Dec 2025Q3 FY26 | Mar 2026Q4 FY26 | Jun 2026Q1 FY27 | Sep 2026Q2 FY27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales₹ crore | 79change on a year before -22% | 85change on a year before +6% | 81change on a year before +6% | 92change on a year before +2% | 87change on a year before +10% | 93change on a year before +9% | 84change on a year before +4% | 88change on a year before -4% | 90change on a year before +3% | 86change on a year before -8% | 91change on a year before +8% | 104change on a year before +18% | 56change on a year before -38% |
| Expenses₹ crore | 62 | 65 | 70 | 68 | 69 | 67 | 60 | 60 | 66 | 64 | 70 | 69 | 88 |
| Change in inventories₹ crore | -16.16 | -20.38 | -90.49 | ||||||||||
| Goods bought for resale₹ crore | 68.34 | 76.05 | 137.58 | ||||||||||
| Employee cost₹ crore | 4.35 | 4.72 | 14.35 | ||||||||||
| Other expenses₹ crore | 13.40 | 8.51 | 26.43 | ||||||||||
| Operating profit₹ crore | 17 | 20 | 11 | 24 | 18change on a year before +6% | 26change on a year before +30% | 24change on a year before +118% | 27change on a year before +13% | 24change on a year before +33% | 22change on a year before -15% | 21change on a year before -13% | 35change on a year before +30% | -32change on a year before -233% |
| Operating margin% of sales | 21.00% | 23.00% | 14.00% | 26.00% | 21.00% | 28.00% | 29.00% | 31.00% | 26.00% | 26.00% | 23.00% | 34.00% | -57.00% |
| Gross margin% of sales | 42.37% | 46.37% | 15.99% | ||||||||||
| Other income₹ crore | 17 | 22 | 10 | 10 | 10 | 11 | 11 | 11 | 9 | 9 | 10 | 9 | -61incl. -68.26 one-time |
| One-time itemswithin other income, ₹ crore | 0.00 | 0.00 | -68.26 | ||||||||||
| Interest₹ crore | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 5 |
| Depreciation₹ crore | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 4 |
| Profit before tax₹ crore | 32 | 41 | 21 | 34 | 28 | 35 | 34 | 37 | 33 | 30 | 30 | 43 | -101 |
| Tax rate% of profit before tax | 27.00% | 36.00% | 31.00% | 24.00% | 26.00% | 28.00% | 14.00% | 26.00% | 26.00% | 46.00% | 16.00% | 25.00% | -23.00% |
| Net profit₹ crore | 24 | 27 | 15 | 26 | 20change on a year before -17% | 25change on a year before -7% | 29change on a year before +93% | 28change on a year before +8% | 24change on a year before +20% | 16change on a year before -36% | 25change on a year before -14% | 32change on a year before +14% | -78change on a year before -425%after a one-time item |
| EPS₹ per share | 8.08 | 9.07 | 5.01 | 8.78 | 6.97change on a year before -14% | 8.69change on a year before -4% | 10.00change on a year before +100% | 9.43change on a year before +7% | 8.27change on a year before +19% | 5.49change on a year before -37% | 8.62change on a year before -14% | 10.99change on a year before +17% | -26.46change on a year before -420% |
Small figure: change on the same quarter a year earlier. Lines that are 0 or blank in every column are not shown.
Sales and profit: growth a year, compounded, to Mar 2026; TTM is the last 12 months. Share price: to the latest close. A span can cross a demerger or an acquisition.
Sales
a year, compounded
- 10 years
- -6%
- 5 years
- -1%
- 3 years
- -2%
- TTM
- -5%
Profit
a year, compounded
- 10 years
- -7%
- 5 years
- 35%
- 3 years
- -3%
- TTM
- -39%
Share price
a year, compounded
- 10 years
- 10%
- 5 years
- 16%
- 3 years
- 34%
- 1 year
- 104%
Return on equity
average over the span
- 10 years
- 8%
- 5 years
- 11%
- 3 years
- 12%
- Last year
- 12%
3 · Quality & value
Answers
The questions investors ask most, each answered first in one line, then shown. From the company's own numbers.
How fast it has been growing
Sales fell 5.1% over the past year.
Meanwhile what it keeps of every 100 rupees of sales slipped from 13.7% to 6.5% over the last four years.
Whether it grew faster than its sector
It grew -2.2% a year against a sector median of 9.9% — 12.2 percentage points slower.
Room to re-rate, or risk of de-rating
At 74.4× earnings it costs 3.2× the market, which pays 23.0× across 2,280 companies we can price.
Its own industry sits at 81.1×, across 5 companies. It is against its own five-year median of 31.2×, the 99th percentile of its own range.
Whether growth justifies the valuation
Its earnings are falling, so growth cannot justify the price.
How it compares with its peers
Against companies the exchange files under the same label (Pharmaceuticals), it ranks 58 of 132 on returns, 123 of 129 on growth, 37 of 132 on margin.
A longer bar is a better rank.
What makes it hard to beat — and is that still true?
A narrow advantage: it earns 16.3% on capital, ahead of 56% of companies filed under the same label.
Whether its growth pays for itself
Yes — Over the last five years it made ₹319 crore of cash from the business, spent ₹1 crore on plant and equipment, and returned ₹315 crore to lenders and shareholders.
But only about 17 of every 100 rupees of profit it reported over 12 years arrived as cash — the rest is tied up.
Peers here are the 132 companies the exchange files under the same label (Pharmaceuticals). That grouping comes from the exchange's filing category, so some of them may not be real rivals.
Business score & profit checks
How strong the business is, and whether its profit is real cash. Facts only, not advice.
Business score
38 out of 100
How strong the business is, in one number. Last changed 20 Nov 2026.
Profit checks: is the profit real cash?
10 of 10 checks clear
Simple checks on the accounts.
Key numbers & peers
Grouped by topic. Each number says what period it is for.
Price
- Market cap
- ₹4,784 Cr
- Prev close
- ₹1,367.60
- 52w High
- ₹2,178
- 52w Low
- ₹631
- Beta
- 0.3
- Price CAGR 1y
- 104.0%
- Price CAGR 3y
- 34.0%
- Price CAGR 5y
- 16.0%
- Price CAGR 10y
- 10.0%
Valuation
- P/E ratioEPS TTM to Sep 2026
- 74.4
- Industry P/E
- 34.7
- P/B ratio
- 6.2
- EV / EBITDA
- 114.7
- Enterprise value
- ₹5,277 Cr
- PEG ratio
- —
- Dividend yield
- 0.0%
Returns
- ROCE
- 16.3%
- ROCE 5y average
- 14.0%
- ROE
- 11.6%
- ROE 3y average
- 12.0%
- ROE last year
- 12.0%
- Return on assets
- 9.5%
Sales, profit & margins
- Annual revenue
- ₹354 Cr
- Annual profit
- ₹93.0 Cr
- EPS
- ₹31.8
- Operating margin
- 26.6%
- Net profit margin
- 26.3%
- EBITDA margin
- 26.6%
- Sales latest quarterSep 2026 quarter
- ₹56.0 Cr
- Profit latest quarterSep 2026 quarter
- -₹78.0 Cr
- OPM latest quarterSep 2026 quarter
- -57.0%
Growth a year
- Sales growth 3y
- -2.2%
- Sales growth 5y
- -1.5%
- Sales growth TTM
- -5.0%
- Profit growth 3y
- -3.3%
- Profit growth 5y
- 34.7%
- Profit growth TTM
- -39.5%
- YoY quarterly sales growthSep 2026 vs Sep 2025
- -37.8%
- YoY quarterly profit growthSep 2026 vs Sep 2025
- -425.0%
Balance sheet
- Book Value
- ₹220
- Face Value
- ₹5.0
- Borrowings
- ₹3.00 Cr
- Total debt
- ₹796 Cr
- Total cash
- ₹253 Cr
- Net debthalf-year 30 Sep · excl. leases
- ₹493 Cr
- Debt / Equity
- 1.0
- Interest coverage
- 103.9
- Reserves / Equity
- 67.1
Cash & payout
- Operating cash flow
- ₹47.0 Cr
- Free cash flow
- ₹46.4 Cr
- FCF yield
- 0.9%
- Net cash flow
- ₹0.00 Cr
- Dividend payout
- 66.0%
Holdings
- Promoter holding
- 70.7%
- FII holding
- 1.2%
- DII holding
- 1.5%
- Public holding
- 26.6%
Enterprise value, step by step
What buying the whole company would cost: its market value, less the cash it holds over its debt. Net debt from the balance sheet of 30 Sep 2026.
- Market cap₹4,784 Cr
- +Net debt₹493 Cr
- =Enterprise value₹5,277 Cr
Peers
| Company | Price ₹ | P/E | Mkt cap ₹ Cr | Div yield | Profit qtr ₹ Cr | Profit change | Sales qtr ₹ Cr | Sales change | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 1,884.90 | 36.8 | 4,52,244 | 0.86% | 1,995 | -36.16% | 16,199 | +11.88% | 20.60% |
| Divi's Laboratories | 11,180.50 | 86.7 | 2,96,283 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharmaceuticals | 4,689.50 | 81.1 | 1,78,370 | 0.82% | 534 | -9.64% | 4,979 | +50.79% | 19.56% |
| Laurus Labs Limited | 2,294.60 | 92.5 | 1,23,977 | 0.09% | 436 | +124.84% | 2,206 | +33.44% | 17.97% |
| Zydus Lifesciences | 1,200.00 | 26.2 | 1,19,760 | 0.08% | 928 | -25.13% | 7,910 | +29.17% | 22.69% |
| Dr Reddy's Laboratories | 1,390.20 | 41.5 | 1,16,082 | 0.58% | 913 | -31.70% | 8,698 | -1.48% | 13.75% |
| Cipla | 1,415.00 | 36.8 | 1,14,311 | 0.93% | 852 | -37.07% | 7,404 | -2.44% | 16.66% |
| Evonile Pharma Limited | 1,367.60 | 74.4 | 4,784 | 0.00% | -78.0 | -425.00% | 56.0 | -37.78% | 16.27% |
| Medianof the whole group of 129, 20 Nov 2026 | 34.9 | 0.09% | +33.42% | +19.60% | 15.01% |
Median: the middle value of the whole peer group of 129 companies. Price and rupee sizes are left blank there, as a middle value of those says little.
Competes with 7 listed companies
Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences
4 · Balance sheet & cash
Balance sheet
What the company owns and what it owes, at each year end and at the filed half-years. ₹ crore.
At Sep 2026: ₹2,278 cr of assets, and who funds them
Shareholders’ own money funds 34% of it; borrowings 35%.
What it owns
- Fixed assets ₹1,310 cr 58%
- Investments ₹50.0 cr 2%
- Owed by customers ₹22.4 cr 1%
- Cash ₹253 cr 11%
- Everything else ₹643 cr 28%
Who funds it
- Shareholders’ money ₹772 cr 34%
- Borrowings ₹796 cr 35%
- Owed to suppliers ₹194 cr 9%
- Everything else ₹516 cr 23%
Each year end, then the filed half-years. Newest year end and newest half-year shaded.
| Line, ₹ crore | Mar 2015FY15 | Mar 2016FY16 | Mar 2017FY17 | Mar 2018FY18 | Mar 2019FY19 | Mar 2020FY20 | Mar 2021FY21 | Mar 2022FY22 | Mar 2023FY23 | Mar 2024FY24 | Mar 2025FY25 | Mar 2026FY26 | Sep 20266 months |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 16 | 16 | 14 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12.34 |
| Reserves | 986 | 1,178 | 906 | 721 | 747 | 708 | 699 | 679 | 763 | 732 | 773 | 805 | 759.38 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 68 | 62 | 24 | 22 | 7 | 5 | 3 | 796.01 |
| Other liabilities | 244 | 239 | 230 | 377 | 223 | 289 | 229 | 242 | 186 | 173 | 158 | 157 | — |
| of which owed to suppliers | — | — | — | — | — | — | — | — | — | — | — | — | 193.66 |
| Total funding | 1,246 | 1,433 | 1,150 | 1,111 | 982 | 1,078 | 1,002 | 958 | 983 | 925 | 948 | 978 | 2,277.66 |
| Fixed assets | 8 | 6 | 6 | 5 | 15 | 76 | 64 | 24 | 19 | 7 | 5 | 3 | 1,310.07 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 50 |
| of which current | — | — | — | — | — | — | — | — | — | — | — | — | 50 |
| Other assetsreceivables, cash, rest | 1,238 | 1,426 | 1,144 | 1,106 | 967 | 1,001 | 938 | 934 | 964 | 918 | 943 | 975 | 917.59 |
| of which owed by customers | — | — | — | — | — | — | — | — | — | — | — | — | 22.35 |
| of which stock | — | — | — | — | — | — | — | — | — | — | — | — | 164.19 |
| of which cash | — | — | — | — | — | — | — | — | — | — | — | — | 252.56 |
| Total assets | 1,246 | 1,433 | 1,150 | 1,111 | 982 | 1,078 | 1,002 | 958 | 983 | 925 | 948 | 978 | 2,277.66 |
Half-year filings list fewer lines: there, Other assets is the total less the three lines above it, and Other liabilities is not filed as one line. Some half-year filings leave out leases, so Borrowings and Fixed assets can be lower than at the year end.
Cash flows
Real money coming in and going out — from the business, from investments and from loans. ₹ crore.
Pick a period to see where its cash went.
In words
- The business brought in ₹46.7 cr, 50% of its operating profit before tax.
- Investing brought in ₹18.0 cr, more than it put in.
- It paid out ₹64.0 cr to shareholders and lenders, 137% of what the business brought in.
- Cash in hand rose by ₹0.00 cr. Free cash flow: ₹46.7 cr.
| Line, ₹ crore | Mar 2015FY15 | Mar 2016FY16 | Mar 2017FY17 | Mar 2018FY18 | Mar 2019FY19 | Mar 2020FY20 | Mar 2021FY21 | Mar 2022FY22 | Mar 2023FY23 | Mar 2024FY24 | Mar 2025FY25 | Mar 2026FY26 | Sep 20266 months |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| From the business | -60.00 | 57.00 | -41.00 | 161.00 | -194.00 | -23.00 | -69.00 | 39.00 | 45.00 | 113.00 | 74.57 | 46.73 | 138.19 |
| From investing | 719 | -630 | 424 | 69 | 274 | 56 | 95 | 87 | -153 | 33 | -3 | 18 | -736.89 |
| From financingdividends, buybacks, loans | -38 | -39 | -332 | -268 | -30 | -41 | -37 | -36 | -30 | -121 | -64 | -64 | 794.44 |
| Net change in cash | 622 | -612 | 51 | -38 | 50 | -9 | -11 | 90 | -139 | 26 | 7 | 0 | 195.74 |
| Spent on assetsfiled at the half-year only | — | — | — | — | — | — | — | — | — | — | — | — | 1,313.24 |
| Free cash flow | -64.00 | 54.00 | -44.00 | 160.00 | -208.00 | -24.00 | -69.00 | 38.00 | 45.00 | 113.00 | 75.32 | 46.68 | -1,175.05 |
| Cash ÷ operating profitbefore tax | — | 168.00% | -164.00% | — | -1617.00% | -192.00% | -256.00% | 144.00% | 69.00% | 174.00% | 82.00% | 50.00% | — |
Free cash flow = cash from the business − spending on assets + what assets sold fetched; the same rule for years and half-years.
Efficiency ratios
How fast customers pay and how well capital earns. Each year, Mar 2015 to Mar 2026.
Debtor days
38 days
Days customers take to pay. Lower is faster.
38 days in FY26, against 41 days in FY25. Over these 12 years: 23 days (FY17) to 45 days (FY24).
Inventory days
98 days
Days stock sits before it is sold.
98 days in FY26, against 74 days in FY25. Over these 12 years: 74 days (FY25) to 119 days (FY21).
Days payable
101 days
Days it takes to pay its suppliers.
101 days in FY26, against 93 days in FY25. Over these 12 years: 87 days (FY17) to 168 days (FY19).
Cash conversion cycle
35 days
Debtor days plus inventory days, less days payable.
35 days in FY26, against 22 days in FY25. Over these 12 years: −45 days (FY18) to 40 days (FY15).
Working capital days
643 days
Days of sales tied up in running the business.
643 days in FY26, against −45 days in FY25. Over these 12 years: −99 days (FY18) to 643 days (FY26).
Return on capital (ROCE)
16%
Operating profit on the capital used.
16% in FY26, against 17% in FY25. Over these 12 years: 5% (FY20) to 22% (FY16).
At the half-year to Sep 2026: debtor days 25.50, inventory days 291.60, days payable 343.90.
5 · Owners & payouts
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
Dividend a share, by the year of its ex-date
No dividend in the last three years; the last went ex on 20 Jul 2023, ₹10 a share.
Share of profit paid as dividend
Each year, Mar 2015 to Mar 2026.
Above 100%: it paid out more than that year’s profit.
Splits, bonuses & buybacks
- Rights 5:1211 Nov 2026
Big trades by funds and insiders
- KARAN BHAGATbulk deal, BSEBought 1,30,000 · at ₹1,670.527 Sep 2026
- KYRUSH INVESTMENTSbulk deal, BSESold 1,30,000 · at ₹1,670.507 Sep 2026
6 · Price & trading
Open interestPRO
Where option traders are positioned on this stock.
7 · Business
About
What the company is, from our own records: where it sits, where its revenue comes from, and where it works.
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Symbol
- EVONILE
- ISIN
- INE234A01025
- Part of
- BSE Healthcare
Sector (1)
- BSE Healthcare
Wider lists and weighting (2)
- BSE 1000
- BSE Total Market Index
Industry numbers
The numbers that matter most in this industry, from the company's own filings and earnings calls. Each one says its period.
Main figures
- Exports share of revenue0.00%
Brand spend
- Ad spendFY to Mar 20260.47%
Revenue and margin
- EBIT marginJun 2026 quarter33.65%
Working capital
- Days sales outstanding12 months to Sep 202624 days
- Working capital to sales12 months to Sep 2026-2.11%
- Customer advancesFY to Mar 2026₹1.77 Cr
Costs
- Employee costSep 2026 quarter25.63%
Profit quality
- Other income shareJun 2026 quarter20.25%
- Interest coverSep 2026 quarter-19.92x
Returns
- RoE12 months to Mar 202611.61%
- RoA12 months to Mar 20269.66%
- Sales to net block12 months to Sep 20260.26x
Leverage
- Net debt to EBITDA12 months to Sep 202610.73x
- Debt service coverFY to Mar 202643.80x
Growth
- Revenue growth (YoY)Sep 2026 quarter-37.78%
Capex
- CapexFY to Mar 2026₹0.32 Cr
- Capex to revenueFY to Mar 20260.09%
How they have moved
EBIT margin · quarterly
Source: Computed from the filings
| Jun 26 | 33.65% | Computed from the filings |
| Mar 26 | 23.08% | Computed from the filings |
| Dec 25 | 25.58% | Computed from the filings |
| Sep 25 | 25.56% | Computed from the filings |
Employee cost · quarterly
Source: Computed from the filings
| Sep 26 | 25.63% | Computed from the filings |
| Jun 26 | 4.54% | Computed from the filings |
| Mar 26 | 4.78% | Computed from the filings |
Other income share · quarterly
Source: Computed from the filings
| Jun 26 | 20.25% | Computed from the filings |
| Mar 26 | 33.21% | Computed from the filings |
| Dec 25 | 30.00% | Computed from the filings |
| Sep 25 | 27.27% | Computed from the filings |
Interest cover · quarterly
Source: Computed from the filings
| Sep 26 | -19.92x | Computed from the filings |
| Jun 26 | 720.50x | Computed from the filings |
| Mar 26 | 431.57x | Computed from the filings |
Revenue growth (YoY) · quarterly
Source: Computed from the filings
| Sep 26 | -37.78% | Computed from the filings |
| Jun 26 | 18.18% | Computed from the filings |
| Mar 26 | 8.33% | Computed from the filings |
| Dec 25 | -7.53% | Computed from the filings |
Capex (fiscal year) · yearly
Source: Computed from the filings
| FY26 | ₹0.32 Cr | Computed from the filings |
| FY25 | -₹0.32 Cr | Computed from the filings |
| FY24 | ₹0.00 Cr | Computed from the filings |
Capex to revenue (fiscal year) · yearly
Source: Computed from the filings
| FY26 | 0.09% | Computed from the filings |
| FY25 | -0.09% | Computed from the filings |
| FY24 | 0.00% | Computed from the filings |
Debt service cover (fiscal year) · yearly
Source: Annual report
| FY26 | 43.80x | Annual report |
| FY25 | 43.20x | Annual report |
Supply chain
Links to other companies, as recorded in our map from filings and announcements. A news event that hits one of them can reach Evonile Pharma Limited through this map.
Buys from · 1
- Novartis Pharma AGPharmaceutical finished products for purchase and import
Competes with · 7 companies
- Sun Pharmaceutical
- Divi's Laboratories
- Torrent Pharmaceuticals
- Laurus Labs
- Zydus Lifesciences
- Dr Reddy's Laboratories
- Cipla
Shaded: the companies compared in Key numbers & peers. Each name opens that company’s page.
8 · News & documents
News and what it reaches
Filings and news about Evonile Pharma Limited, and bigger events that reach it through its owners, rivals, customers or suppliers. Newest first. Open one to see how the effect spreads.
11 Sep 202604:38 IST
Novartis India enters brand acquisition deal; NALCO partners EGA for Odisha smelter expansion
Novartis India bought brands to grow its portfolio while NALCO tied up with EGA to expand its Odisha smelter, two company-specific positives.
News reportHow it spreads
Who it hits first
- Novartis India scales its domestic brand portfolio
- NALCO's EGA tie-up de-risks smelter expansion tech and capital
- Pharma and aluminium peers see no spillover
Who may gain
- Odisha gains smelter capex and jobs
- Novartis India's field force gains more to sell
Along the supply chain
Downstream
Aluminium buyers gain long-term domestic supply.
Upstream
Smelter-equipment and construction vendors gain NALCO orders.
Where demand moves
Business
NALCO procures construction and equipment for expansion; Novartis integrates acquired brands into distribution.
How it spreads across sectors
Healthcare
Novartis brand deal only; no sector read
Metals & Mining
NALCO expansion adds structural supply
When it plays out
Short term
Watch deal financials and EGA equity structure.
Medium term
Smelter output and brand scale compound over 3-5 years.
31 Jul 202604:12 IST
Novartis India recast as ChrysCapital-led buyout of Swiss parent's stake completes
News reportHow it spreads
Who it hits first
- Novartis India (NOVARTIND) is the company affected - ownership passes from Novartis AG to a ChrysCapital-led private-equity consortium, and the company will be rebranded.
Along the supply chain
Downstream
No direct downstream link - hospitals and distributors that buy its medicines face no supply change from the ownership transfer.
Upstream
No direct upstream link - a change in who owns Novartis India does not alter what raw materials or active ingredients it buys.
Where demand moves
Business
No supply-chain demand shift - this is an ownership change at one drugmaker and does not move orders toward or away from pharma peers like Cipla, Lupin or Sun Pharma.
How it spreads across sectors
Healthcare
Minimal ripple - a single already-priced MNC-pharma buyout completion does not move the broader pharma sector.
When it plays out
Immediate
Little price impact expected - the catalyst played out in Feb-March 2026.
Short term
Watch for the rebranding and any change in strategy or capital allocation under the new private-equity owner.
AI-written from public sources · Information, not advice · Not SEBI-registered
Documents
Earnings calls, results presentations and annual reports, straight from the company and the exchanges.
Earnings calls · 2
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.